Edition:
United States

PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

30.01USD
24 May 2018
Change (% chg)

-- (--)
Prev Close
$30.01
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
334,113
52-wk High
$33.19
52-wk Low
$12.17

Latest Key Developments (Source: Significant Developments)

PTC Therapeutics Announces Proposed Public Offering Of Common Stock
Tuesday, 27 Mar 2018 04:04pm EDT 

March 27 (Reuters) - Ptc Therapeutics Inc ::PTC THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.PTC THERAPEUTICS INC - COMMENCING A PUBLIC OFFERING OF 4 MILLION SHARES OF ITS COMMON STOCK.  Full Article

Ptc Therapeutics Says ‍Firefish Study Of RG7916 In Type 1 Spinal Muscular Atrophy Patients Transitioned Into Pivotal Phase With Dosing First Patient​
Thursday, 15 Mar 2018 08:00am EDT 

March 15 (Reuters) - Ptc Therapeutics Inc ::PTC THERAPEUTICS INC - ‍FIREFISH STUDY OF RG7916 IN TYPE 1 SPINAL MUSCULAR ATROPHY PATIENTS TRANSITIONED INTO PIVOTAL PHASE WITH DOSING FIRST PATIENT​.  Full Article

PTC Therapeutics Q4 Revenue $78.0 Million
Tuesday, 6 Mar 2018 04:01pm EST 

March 6 (Reuters) - PTC Therapeutics Inc ::‍TOTAL REVENUES FOR Q4 OF 2017 WERE $78.0 MILLION COMPARED TO $25.2 MILLION IN Q4 OF 2016​.SEES ‍FULL YEAR 2018 NET PRODUCT REVENUES TO BE BETWEEN $260 AND $295 MILLION​.‍PTC ANTICIPATES TRANSLARNA NET PRODUCT REVENUE FOR FULL YEAR 2018 TO BE BETWEEN $170 AND $185 MILLION​.‍PTC PROJECTS A 5-YEAR (DECEMBER 31, 2022) COMPOUND ANNUAL GROWTH RATE OF 15% FOR NET PRODUCT REVENUES​.‍PTC ANTICIPATES EMFLAZA NET PRODUCT REVENUE FOR FULL YEAR 2018 TO BE BETWEEN $90 AND $110 MILLION​.QTRLY ‍SHR $ 0.03​.Q4 REVENUE VIEW $74.4 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

PTC Therapeutics Receives Formal Dispute Resolution Request Decision
Tuesday, 20 Feb 2018 08:00am EST 

Feb 20 (Reuters) - PTC Therapeutics Inc ::PTC THERAPEUTICS RECEIVES FORMAL DISPUTE RESOLUTION REQUEST DECISION FROM THE FDA'S OFFICE OF NEW DRUGS.PTC THERAPEUTICS INC - OFFICE OF NEW DRUGS OF U.S. FDA DENIED PTC'S APPEAL OF COMPLETE RESPONSE LETTER IN RELATION TO NDA FOR ATALUREN.PTC THERAPEUTICS INC - OFFICE OF NEW DRUGS RECOMMENDED A POSSIBLE PATH FORWARD FOR ATALUREN NDA SUBMISSION BASED ON ACCELERATED APPROVAL PATHWAY.PTC THERAPEUTICS- LETTER FROM OFFICE OF NEW DRUGS ADDS CO'S STUDY 041 COULD SERVE AS CONFIRMATORY POST-APPROVAL TRIAL NEEDED FOR ACCELERATED APPROVAL.PTC THERAPEUTICS INC - PTC CURRENTLY INTENDS TO MAINTAIN PATIENTS IN U.S. CURRENTLY RECEIVING ATALUREN FOR NMDMD.  Full Article

PTC Therapeutics reports qtrly net loss per share basic and diluted of $0.82
Thursday, 2 Nov 2017 04:01pm EDT 

Nov 2 (Reuters) - Ptc Therapeutics Inc ::Qtrly total revenues $41.9 million versus $22.98 million.Qtrly net loss per share basic and diluted $0.82.Q3 earnings per share view $-0.68, revenue view $42.2 million -- Thomson Reuters I/B/E/S.Increasing 2017 revenue guidance to $160-$185M​.FY2017 revenue view $173.4 million -- Thomson Reuters I/B/E/S.  Full Article

PTC THERAPEUTICS ANNOUNCES DATA FROM PART 1 OF SUNFISH TRIAL
Tuesday, 3 Oct 2017 10:12am EDT 

Oct 3 (Reuters) - PTC Therapeutics Inc ::RG7916 INCREASED SMN PROTEIN PRODUCTION IN SUNFISH CLINICAL TRIAL IN PATIENTS WITH TYPE 2/3 SPINAL MUSCULAR ATROPHY.PTC THERAPEUTICS INC - RG7916 REMAINS WELL-TOLERATED IN PATIENTS AT ALL DOSES AND THERE HAVE BEEN NO DRUG-RELATED SAFETY FINDINGS LEADING TO WITHDRAWAL​.PTC THERAPEUTICS INC SAYS ANNOUNCED DATA FROM PART 1 OF SUNFISH TRIAL OF RG7916 IN TYPE 2/3 SPINAL MUSCULAR ATROPHY PATIENTS​.  Full Article

PTC Therapeutics files for potential mixed shelf; size not disclosed - SEC filing‍​
Thursday, 24 Aug 2017 06:07pm EDT 

Aug 24 (Reuters) - Ptc Therapeutics Inc :Files for potential mixed shelf; size not disclosed - SEC filing‍​.  Full Article

PTC Therapeutics qtrly loss per share $0.44
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Ptc Therapeutics Inc :Ptc therapeutics - qtrly total revenues $48 million versus $15.6 million; qtrly loss per share $0.44; sees fy translarna net sales $120 million - $140 million ‍​.Q2 earnings per share view $-1.28, revenue view $28.8 million -- Thomson Reuters I/B/E/S.Fy2017 revenue view $142.2 million -- Thomson Reuters I/B/E/S.  Full Article

Great Point Partners Llc reports 5.24 percent passive stake in PTC Therapeutics Inc
Friday, 16 Jun 2017 04:09pm EDT 

June 16 (Reuters) - Great Point Partners lLC::Great Point Partners LLC reports 5.24 percent passive stake in PTC Therapeutics Inc <<>> as of June 6, 2017 .  Full Article

PTC enters into credit and security agreement for senior secured term loan facility
Monday, 8 May 2017 07:44am EDT 

May 8 (Reuters) - Ptc Therapeutics Inc :Ptc therapeutics inc- on may 5, entered into a credit and security agreement for a senior secured term loan facility of $60.0 million - sec filing.Ptc therapeutics inc- final maturity date under credit agreement is may 1, 2021.Ptc therapeutics inc - on loan facility of $60.0 million, $40.0 million was drawn by company on may 5, 2017.Ptc therapeutics-$20.0 million under facility available upon co's demonstration, on/prior to dec 31, 2018, of net product revenue equaling/exceeding $120 million.  Full Article

BRIEF-PTC Therapeutics Reports Q1 Loss Per Share $0.46

* PTC THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE